Top Markets
#1 MowCat MowCat +26.83%
#2 OriginTrail OriginTrail +20.91%
#3 Wrapped STX (Velar) Wrapped STX (Velar) +20.26%
#4 Pons Pons +14.01%
#5 Wrapped NXM Wrapped NXM +10.13%
#6 Collector Crypt Collector Crypt +7.35%
#7 Geodnet Geodnet +7.05%
#8 Hydration Hydration +6.06%
#9 MarsCoin MarsCoin +4.96%
#10 Pharos Pharos +4.80%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Pardes Biosciences, Inc. Pardes Biosciences, Inc.

Pardes Biosciences, Inc.

PRDS
Rank in Stocks #20774
Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated... Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, developing, and marketing groundbreaking treatments. The company's core objective is to improve outcomes for patients battling life-threatening illnesses. Its primary investigational therapy, PBI-0451, is currently progressing through clinical development with the aim of both treating and preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and their related health issues. Established in 2020, Pardes Biosciences maintains its corporate headquarters in Carlsbad, California.
Share Price
$2.16
Last synced: 2023-09-08
Market Cap
$122.36M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Pardes Biosciences, Inc. (PRDS)

Category

Healthcare
P/E ratio for Pardes Biosciences, Inc. (PRDS)
P/E ratio as of 2026 TTM: 0
According to Pardes Biosciences, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Pardes Biosciences, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.